# Biolinq

> Biolinq is a San Diego medical device company developing intradermal wearable biosensors. Its lead product, Biolinq Shine, combines glucose range information, activity and sleep in a forearm patch with a built-in color-changing light and optional app. Shine received FDA De Novo classification in 2025 and over-the-counter clearance in September 2026 for adults 22 and older not using insulin.

- **Founded:** 2012
- **Headquarters:** San Diego, United States
- **Founders:** Jared Tangney (Co-founder, President & CTO), Joshua Windmiller (Co-founder; formerly CTO)
- **Products:** Biolinq Shine, Multi-analyte biosensor platform
- **Notable:** FDA De Novo classification for Shine on September 23, 2025, establishing a Class II glucose range monitoring system category., FDA 510(k) OTC clearance in September 2026; company announcement dated September 24., US$100 million Series B in 2021, US$58 million financing in 2024 and US$100 million Series C in 2025.

## Products & services

- **Biolinq Shine** — An intradermal glucose range monitoring patch with a color-changing LED, activity and sleep information, and an optional companion app. FDA De Novo classification in 2025; OTC clearance in 2026 for adults 22 and older not on insulin.
- **Multi-analyte biosensor platform** — Research platform using arrays of miniature electrochemical sensors; glucose/lactate and other biomarker work is distinct from Shine’s cleared glucose indication.

## Achievements

- FDA De Novo classification for Shine on September 23, 2025, establishing a Class II glucose range monitoring system category.
- FDA 510(k) OTC clearance in September 2026; company announcement dated September 24.
- US$100 million Series B in 2021, US$58 million financing in 2024 and US$100 million Series C in 2025.
- As Electrozyme, received a CONNECT Most Innovative New Product award in 2014.

## Latest updates

- **2026-09** — Biolinq announced FDA 510(k) clearance allowing OTC use of Shine for adults 22 and older not on insulin.
- **2026-01** — Rebecca Gottlieb discussed biosensing research and innovation leadership on DeviceTalks’ Women in MedTech podcast.
- **2025-09** — Biolinq announced FDA De Novo classification of Shine.
- **2025-04** — Closed a US$100 million Series C led by Alpha Wave Ventures.

## Links

- Website: https://biolinq.com
- LinkedIn: https://www.linkedin.com/company/biolinq/
- Facebook: https://facebook.com/biolinqcgm/

---

Profile page: https://yespress.io/biolinq
Published by YesPress — https://yespress.io
Last updated: 2026-10-16